Protection against aspirin-induced antral and duodenal damage with enprostil. A double-blind endoscopic study.
Prostaglandins protect against aspirin-induced damage to the gastrointestinal tract. This study tested the ability of enprostil, a synthetic analog of prostaglandin E2, given concurrently to prevent gastroduodenal injury. Twenty-four healthy subjects were randomly assigned to one of three groups. All received aspirin 650 mg q.i.d. for 5 days. One group received placebo and the other groups were given either 7 or 70 micrograms of enprostil b.i.d. for 5 days. Upper endoscopy was performed at entry and 2 h after the final dose of aspirin. Enprostil 70 micrograms b.i.d. afforded significant protection of both the antral and duodenal mucosa. The 7-micrograms dose protected only the antral mucosa. Side effects were not observed with the lower dose of enprostil. Serum salicylate levels did not differ significantly between the groups.
D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000037:antagonists & inhibitors*; D004341:Drug Evaluation; D004386:Duodenum; D016620:Enprostil; D005260:Female; D005748:Gastric Fundus; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008297:Male; D011459:Prostaglandins E, Synthetic / Q000009:adverse effects / Q000494:pharmacology*; D011706:Pyloric Antrum; D011897:Random Allocation; D012459:Salicylates / Q000097:blood; D020156:Salicylic Acid
D011459:Prostaglandins E, Synthetic; D012459:Salicylates; D016620:Enprostil; D020156:Salicylic Acid; D001241:Aspirin